CEBPZ and acute myeloid leukemia: Although the current data do not support the use of KIT mutational status in clinical guidance (in terms of therapeutic interventions), the data have been included in the National Comprehensive Cancer Network Guidelines as a prognostic marker, where the KIT mutation can transform CBF-AML patients from favorable-risk AML to intermediate-risk AML [18].